

VADODAR

For Immediate Release Revenue at Rs 1326 crores Net Profit at Rs 165 crores India Business up 57%

Vadodara July 26th, 2021

Alembic Pharmaceuticals Limited reported its consolidated financial results for the quarter ending 30th June 2021.

Financial Highlights for Q1FY22

- Net Sales down 1% at Rs 1326 crores
- Profit before tax down 46% at Rs 199 crores
- Net Profit down 45% at Rs 165 crores

Mr. Pranav Amin, Managing Director, Alembic Pharmaceuticals Limited said

"The India business grew exceptionally well and outpaced the Industry, we hope to see this momentum continuing due to the initiatives undertaken recently. The US business faced price erosion due to increased competition. However, our long term view of the US market remains intact."

Operational Highlights

International Business

- US Generics de-grew 38% to Rs 369 crores in the quarter.
- Ex-US International Formulations grew 13% to Rs 197 crores in the quarter.
- 7 ANDA approvals received during the quarter, Cumulative ANDA approvals at 146 (including 18 tentative).
- 3 ANDA filings during the quarter; Cumulative ANDA filings at 212.

India Branded Business

- India Branded Business for the quarter grew by 57% to Rs 481 crores
- The Acute segment as well as the Specialty segment grew faster than the represented pharmaceutical market.



API Business

- API business grew 6 % to Rs 279 crores in the quarter.
- 1 DMF was filed in the quarter, Cumulative DMF fillings at 118.

Summary of Total Revenue is as under:

(Rs in Crores)

Particulars	Q1 FY22	Q1 FY21	% Change
Formulation			
USA	369	596	(38%)
EX-USA	197	175	13%
India	481	306	57%
API	279	264	6%
Total	1326	1341	(1%)

The Profit break-up is as under:

(Rs in Crores)

VADODARA 390 003

Particulars	Q1 FY22	Q1 FY21	% Change
EBITDA Pre R&D	406	549	(26%)
EBITDA Pre R&D %	31%	41%	
EBITDA Post R&D	254	416	(39%)
EBITDA Post R&D %	19%	31%	
Profit Before Tax	199	368	(46%)
Net Profit after Tax	165	301	(45%)

About Alembic Pharmaceuticals Limited

Alembic Pharmaceuticals Limited, a vertically integrated research and development pharmaceutical company, has been at the forefront of healthcare since 1907. Headquartered in India, Alembic is a publicly listed company that manufactures and markets generic pharmaceutical products all over the world. Alembic's state of the art research and manufacturing facilities are approved by regulatory authorities of many developed countries including the US FDA. Alembic is one of the leaders in branded





generics in India. Alembic's brands, marketed through a marketing team of over 5000 are well recognized by doctors and patients.

Information about the company can be found at www.alembicpharmaceuticals.com; (reuters:ALEM.NS) (bloomberg:ALPM) (nse:APLLTD) (bse:533573)

For more information contact:

Ajay Kumar Desai Mitanshu Shah

Phone: +91 22 - 306 11681 Phone: +91 265 - 6637630

